Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Outperforming the Russell Midcap Growth Index's 5.84% decline through resilient selection in healthcare and communication services, while actively deploying into enterprise software on pullbacks.
Full Quick Take
Outperforming the Russell Midcap Growth Index's 5.84% decline through resilient selection in healthcare and communication services, while actively deploying into enterprise software on pullbacks.
Core holdings SpaceX, Filtronic, and ImmunityBio trade at compelling valuations: SpaceX at 23x earnings with 87% growth, Filtronic at 12x forward earnings at factory capacity, ImmunityBio addressing $43bn+ market.
Full Quick Take
Core holdings SpaceX, Filtronic, and ImmunityBio trade at compelling valuations: SpaceX at 23x earnings with 87% growth, Filtronic at 12x forward earnings at factory capacity, ImmunityBio addressing $43bn+ market.
Source Capital is pivoting away from the AI-driven market rally, reducing exposure to semiconductor and data center beneficiaries despite long-term bullish views on the technology.
Full Quick Take
Source Capital is pivoting away from the AI-driven market rally, reducing exposure to semiconductor and data center beneficiaries despite long-term bullish views on the technology.
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Full Quick Take
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Harbor Mid Cap Value outperformed in Q2 2026 through disciplined stock selection despite value lagging growth. AI infrastructure holdings TD Synnex, Arrow Electronics, and Hewlett Packard Enterprise surged 50-90% on semiconductor and data center demand.
Full Quick Take
Harbor Mid Cap Value outperformed in Q2 2026 through disciplined stock selection despite value lagging growth. AI infrastructure holdings TD Synnex, Arrow Electronics, and Hewlett Packard Enterprise surged 50-90% on semiconductor and data center demand.
Slightly trailing the S&P 500 on allocation effects. AI infrastructure drove market leadership, with the Fund adding semiconductor exposure through AMD and Micron positions.
Full Quick Take
Slightly trailing the S&P 500 on allocation effects. AI infrastructure drove market leadership, with the Fund adding semiconductor exposure through AMD and Micron positions.
Franklin Growth Opportunities Fund outperformed in Q2 2026 with a 20.9% return, led by Micron Technology's AI-driven surge and SpaceX's successful IPO.
Full Quick Take
Franklin Growth Opportunities Fund outperformed in Q2 2026 with a 20.9% return, led by Micron Technology's AI-driven surge and SpaceX's successful IPO.
CDT implements first-ever defensive hedging against technology sector, viewing AI as an unsustainable bubble with OpenAI burning -$21B annually and Meta wasting $125-145B with no results. Semiconductors at 19.7% of S&P 500 face earnings bust when capital discipline returns.
Full Quick Take
CDT implements first-ever defensive hedging against technology sector, viewing AI as an unsustainable bubble with OpenAI burning -$21B annually and Meta wasting $125-145B with no results. Semiconductors at 19.7% of S&P 500 face earnings bust when capital discipline returns.
FPA Crescent is executing a contrarian pivot away from AI-driven market leaders despite positive long-term technology views, scaling back semiconductor and data center exposure due to expanded valuations and advanced capital cycle stage.
Full Quick Take
FPA Crescent is executing a contrarian pivot away from AI-driven market leaders despite positive long-term technology views, scaling back semiconductor and data center exposure due to expanded valuations and advanced capital cycle stage.
Murata, Infineon, MediaTek and TSMC drove returns on multi-year AI infrastructure buildout. The fund deployed capital into biopharma recovery (Merck, Pharmaron), China automation (Inovance), and offshore wind turnaround (Orsted).
Full Quick Take
Murata, Infineon, MediaTek and TSMC drove returns on multi-year AI infrastructure buildout. The fund deployed capital into biopharma recovery (Merck, Pharmaron), China automation (Inovance), and offshore wind turnaround (Orsted).
Intel, Murata and MediaTek drove outperformance on AI infrastructure demand. The fund deployed capital aggressively, initiating thirteen positions including utilities, biotech tools and Chinese automation plays.
Full Quick Take
Intel, Murata and MediaTek drove outperformance on AI infrastructure demand. The fund deployed capital aggressively, initiating thirteen positions including utilities, biotech tools and Chinese automation plays.
Crushing the benchmark by 549 basis points on AI-driven semiconductor strength. The managers repositioned toward idiosyncratic growth stories, adding AI infrastructure plays while exiting disruption-vulnerable software names.
Full Quick Take
Crushing the benchmark by 549 basis points on AI-driven semiconductor strength. The managers repositioned toward idiosyncratic growth stories, adding AI infrastructure plays while exiting disruption-vulnerable software names.
Driven by European banks, Irish homebuilders, and a Capstone Copper recovery. The manager actively trimmed copper holdings on valuation concerns despite strong fundamentals, while initiating CSL at attractive multiples.
Full Quick Take
Driven by European banks, Irish homebuilders, and a Capstone Copper recovery. The manager actively trimmed copper holdings on valuation concerns despite strong fundamentals, while initiating CSL at attractive multiples.
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Full Quick Take
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Full Quick Take
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Full Quick Take
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Full Quick Take
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Exiting Dave at peak valuations and Root after industry headwinds deepened, while maintaining conviction in Liquidia ahead of a catalyst and initiating positions in mispriced Celsius and Light & Wonder.
Full Quick Take
Exiting Dave at peak valuations and Root after industry headwinds deepened, while maintaining conviction in Liquidia ahead of a catalyst and initiating positions in mispriced Celsius and Light & Wonder.
Trailing the benchmark's 28.98% gain driven by historically narrow, speculative AI-related leadership. Biotechnology holdings delivered exceptional performance, contributing over 600 basis points, while defense and industrial holdings also performed well.
Full Quick Take
Trailing the benchmark's 28.98% gain driven by historically narrow, speculative AI-related leadership. Biotechnology holdings delivered exceptional performance, contributing over 600 basis points, while defense and industrial holdings also performed well.
Manager increasingly concerned AI capex boom is unsustainable, requiring unrealistic revenue growth with risk of violent crash given market concentration.
Full Quick Take
Manager increasingly concerned AI capex boom is unsustainable, requiring unrealistic revenue growth with risk of violent crash given market concentration.
Portfolio underperformed despite strong operational progress across holdings, with businesses now trading at lower valuations. MercadoLibre accelerated growth through reinvestment while Spotify expanded margins with AI monetization.
Full Quick Take
Portfolio underperformed despite strong operational progress across holdings, with businesses now trading at lower valuations. MercadoLibre accelerated growth through reinvestment while Spotify expanded margins with AI monetization.
Driven by Liquidia's fivefold gain as its drug launch succeeded spectacularly. The concentrated portfolio approach continues to work: largest positions consistently outperform.
Full Quick Take
Driven by Liquidia's fivefold gain as its drug launch succeeded spectacularly. The concentrated portfolio approach continues to work: largest positions consistently outperform.
Semiconductors surged 90% as AI infrastructure demand exploded. The manager trimmed AI exposure late quarter expecting consolidation but remains bullish on the second half given strong fundamentals and broadening market leadership.
Full Quick Take
Semiconductors surged 90% as AI infrastructure demand exploded. The manager trimmed AI exposure late quarter expecting consolidation but remains bullish on the second half given strong fundamentals and broadening market leadership.
Modestly outperforming despite market leadership favoring low-quality companies. Health care and AI infrastructure holdings drove performance, with biotechnology and semiconductor positions delivering strong results.
Full Quick Take
Modestly outperforming despite market leadership favoring low-quality companies. Health care and AI infrastructure holdings drove performance, with biotechnology and semiconductor positions delivering strong results.
American Century Small Cap Value underperformed in Q2 2026.19%, primarily due to missing AI-driven technology rallies and energy sector weakness from lower oil prices. Semiconductor equipment providers and AI-enabled advertising technology were bright spots.
Full Quick Take
American Century Small Cap Value underperformed in Q2 2026.19%, primarily due to missing AI-driven technology rallies and energy sector weakness from lower oil prices. Semiconductor equipment providers and AI-enabled advertising technology were bright spots.
Outperforming on strong semiconductor and biotech stock selection. Health care outperformed the sector by 16 percentage points driven by biotech holdings.
Full Quick Take
Outperforming on strong semiconductor and biotech stock selection. Health care outperformed the sector by 16 percentage points driven by biotech holdings.
Madison Small Cap Fund underperformed the Russell 2000's 21.5% Q2 rally. Recent software investments and healthcare positions dragged performance despite strong conviction in their long-term value.
Full Quick Take
Madison Small Cap Fund underperformed the Russell 2000's 21.5% Q2 rally. Recent software investments and healthcare positions dragged performance despite strong conviction in their long-term value.
Riverwater's Small Cap strategy trailed the Russell 2000's 21% Q2 surge as markets rewarded speculation over quality. Energy stock selection drove outperformance through services positioning, while healthcare lagged as speculative biotech rallied.
Full Quick Take
Riverwater's Small Cap strategy trailed the Russell 2000's 21% Q2 surge as markets rewarded speculation over quality. Energy stock selection drove outperformance through services positioning, while healthcare lagged as speculative biotech rallied.
Outperforming its benchmark by 570 basis points. AI infrastructure drove performance as the fund capitalized on accelerating investment in data center compute capacity, with Nebius Group and Credo Technology as top contributors.
Full Quick Take
Outperforming its benchmark by 570 basis points. AI infrastructure drove performance as the fund capitalized on accelerating investment in data center compute capacity, with Nebius Group and Credo Technology as top contributors.
Parnassus Growth Equity outperformed in Q2 2026 on strong semiconductor and AI infrastructure holdings, rotating capital into biotechnology and data center positions with clearer growth paths.
Full Quick Take
Parnassus Growth Equity outperformed in Q2 2026 on strong semiconductor and AI infrastructure holdings, rotating capital into biotechnology and data center positions with clearer growth paths.
Fund underperformed in Q2 as extreme market concentration favored narrow AI capex trade, but manager maintains five-year conviction. Portfolio declines driven by valuation compression, not earnings deterioration, creating coiled spring as intrinsic value rises while prices fall.
Full Quick Take
Fund underperformed in Q2 as extreme market concentration favored narrow AI capex trade, but manager maintains five-year conviction. Portfolio declines driven by valuation compression, not earnings deterioration, creating coiled spring as intrinsic value rises while prices fall.
Rebounding from Q1 losses by diversifying into 16 positions across healthcare, biotech, and consumer sectors while aggressively shorting overvalued names.
Full Quick Take
Rebounding from Q1 losses by diversifying into 16 positions across healthcare, biotech, and consumer sectors while aggressively shorting overvalued names.
ClearBridge Mid Cap Growth outperformed in Q2 2026 by identifying durable value in AI infrastructure bottlenecks like memory and data connectivity while capturing industrial recovery in equipment rental and modular space.
Full Quick Take
ClearBridge Mid Cap Growth outperformed in Q2 2026 by identifying durable value in AI infrastructure bottlenecks like memory and data connectivity while capturing industrial recovery in equipment rental and modular space.
The Strategy benefited from AI-exposed holdings in semiconductors and data center infrastructure but faced headwinds from software disruption concerns and idiosyncratic health care weakness.
Full Quick Take
The Strategy benefited from AI-exposed holdings in semiconductors and data center infrastructure but faced headwinds from software disruption concerns and idiosyncratic health care weakness.
Southeastern runs a concentrated 17-stock portfolio trading at high-50s percent of value, positioned as contrarians during historic market speculation.
Full Quick Take
Southeastern runs a concentrated 17-stock portfolio trading at high-50s percent of value, positioned as contrarians during historic market speculation.
Outperforming the UK market by 5% as capital rotated back to quality. The fund targets high-quality compounders with 37% ROE and 5.5% free cash flow yields trading at attractive valuations.
Full Quick Take
Outperforming the UK market by 5% as capital rotated back to quality. The fund targets high-quality compounders with 37% ROE and 5.5% free cash flow yields trading at attractive valuations.
Southeastern's Global Fund significantly underperformed in Q2 2026 due to avoiding overvalued AI and technology stocks the manager views as bubble territory. The concentrated 20-stock portfolio trades at mid-50s% P/V with the lowest multiples of real free cash flow.
Full Quick Take
Southeastern's Global Fund significantly underperformed in Q2 2026 due to avoiding overvalued AI and technology stocks the manager views as bubble territory. The concentrated 20-stock portfolio trades at mid-50s% P/V with the lowest multiples of real free cash flow.
Jacob Asset Management is positioned for the acceleration of agentic AI adoption, which they view as a transformational force rivaling the dot-com boom.
Full Quick Take
Jacob Asset Management is positioned for the acceleration of agentic AI adoption, which they view as a transformational force rivaling the dot-com boom.